EGFR Non Small Cell Lung Cancer Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Avistone Pharma, Black Diamond Therapeutics, Bayer, Bridge

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, EGFR Non Small Cell Lung Cancer pipeline constitutes 37+ key companies continuously working towards developing 40+ EGFR Non Small Cell Lung Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The EGFR Non Small Cell Lung Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"EGFR Non Small Cell Lung Cancer Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the EGFR Non Small Cell Lung Cancer Market.

Some of the key takeaways from the EGFR Non Small Cell Lung Cancer Pipeline Report:

*
Companies across the globe are diligently working toward developing novel EGFR Non Small Cell Lung Cancer treatment therapies with a considerable amount of success over the years.

*
EGFR Non Small Cell Lung Cancer companies working in the treatment market are Avistone Pharmaceuticals, Black Diamond Therapeutics, Bayer, Bridge Therapeutics, RedCloud Bio, J Ints Bio, Cullinan Oncology, TYK Medicine, and others, are developing therapies for the EGFR Non Small Cell Lung Cancer treatment

*
Emerging EGFR Non Small Cell Lung Cancer therapies in the different phases of clinical trials are- PLB1004, BDTX-1535, BAY2927088, BBT-176, H002, JIN-A02, CLN-081, TY-9591, and others are expected to have a significant impact on the EGFR Non Small Cell Lung Cancer market in the coming years.

*
In March 2024, InnoCare Pharma has administered the first dose in a Phase Ib clinical trial evaluating the combination of its drug ICP-189 with ArriVent BioPharma's furmonertinib for treating non-small cell lung cancer (NSCLC). ICP-189, developed by InnoCare, is an allosteric inhibitor of Src Homology 2 domain containing protein tyrosine phosphatase (SHP2), while furmonertinib is a brain-penetrant, mutation-selective inhibitor of the epidermal growth factor receptor (EGFR). ICP-189 is intended to target solid tumors, either as a monotherapy or in combination with other antitumor agents.

*
In September 2023, The Janssen Pharmaceutical Companies of Johnson & Johnson announced positive top-line results from the Phase 3 MARIPOSA study. This study evaluated RYBREVANT Registered (amivantamab-vmjw), a bispecific antibody targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), combined with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), against osimertinib as a first-line treatment for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).

*
In October 2023, the Janssen Pharmaceutical Companies of Johnson & Johnson announced the findings of the Phase 3 MARIPOSA-2 study, which demonstrated that the combination of chemotherapy and RYBREVANT Registered (amivantamab-vmjw), given with or without lazertinib, reduced the risk of death or disease progression by 56% and 56%, respectively (Hazard Ratio [HR]=0.44; 95 percent Confidence Interval [CI], 0.35-0.56; p value P

*
In June 2022, In order to determine the safety and effectiveness of TY-9591 versus Osimertinib in treating patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is known to be positive for the EGFR sensitizing mutation (EGFRm), treatment-naive, and eligible for first-line treatment with an EGFR-TKI, TYK Medicines started a Phase III, double-blind, randomised study.

EGFR Non Small Cell Lung Cancer Overview

EGFR-positive non-small cell lung cancer (NSCLC) is a subtype of lung cancer characterized by mutations in the epidermal growth factor receptor (EGFR) gene

Get a Free Sample PDF Report to know more about EGFR Non Small Cell Lung Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight [https://www.delveinsight.com/report-store/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging EGFR Non Small Cell Lung Cancer Drugs Under Different Phases of Clinical Development Include:

*
PLB1004: Avistone Pharmaceuticals

*
BDTX-1535: Black Diamond Therapeutics

*
BAY2927088: Bayer

*
BBT-176: Bridge Therapeutics

*
H002: RedCloud Bio

*
JIN-A02: J Ints Bio

*
CLN-081: Cullinan Oncology

*
TY-9591: TYK Medicine

EGFR Non Small Cell Lung Cancer Route of Administration

EGFR Non Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

EGFR Non Small Cell Lung Cancer Molecule Type

EGFR Non Small Cell Lung Cancer Products have been categorized under various Molecule types, such as

*
Recombinant fusion proteins

*
Small molecule

*
Monoclonal antibody

*
Peptide

*
Polymer

*
Gene therapy

EGFR Non Small Cell Lung Cancer Pipeline Therapeutics Assessment

*
EGFR Non Small Cell Lung Cancer Assessment by Product Type

*
EGFR Non Small Cell Lung Cancer By Stage and Product Type

*
EGFR Non Small Cell Lung Cancer Assessment by Route of Administration

*
EGFR Non Small Cell Lung Cancer By Stage and Route of Administration

*
EGFR Non Small Cell Lung Cancer Assessment by Molecule Type

*
EGFR Non Small Cell Lung Cancer by Stage and Molecule Type

DelveInsight's EGFR Non Small Cell Lung Cancer Report covers around 40+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further EGFR Non Small Cell Lung Cancer product details are provided in the report. Download the EGFR Non Small Cell Lung Cancer pipeline report to learn more about the emerging EGFR Non Small Cell Lung Cancer therapies [https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the EGFR Non Small Cell Lung Cancer Therapeutics Market include:

Key companies developing therapies for EGFR Non Small Cell Lung Cancer are - Summit Therapeutics, Arcus Biosciences, GlaxoSmithKline, Pfizer, AstraZeneca, Seagen, MacroGenics, Roche, Qilu Pharmaceutical, Shandong New age Pharmaceutical, Symphogen, and others.

EGFR Non Small Cell Lung Cancer Pipeline Analysis:

The EGFR Non Small Cell Lung Cancer pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of EGFR Non Small Cell Lung Cancer with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for EGFR Non Small Cell Lung Cancer Treatment.

*
EGFR Non Small Cell Lung Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
EGFR Non Small Cell Lung Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the EGFR Non Small Cell Lung Cancer market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about EGFR Non Small Cell Lung Cancer drugs and therapies [https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

EGFR Non Small Cell Lung Cancer Pipeline Market Drivers

*
Increasing prevalence of non-small cell lung cancer, increasing new drug approvals, increase in frequency of diagnosis of NSCLC are some of the important factors that are fueling the EGFR Non Small Cell Lung Cancer Market.

EGFR Non Small Cell Lung Cancer Pipeline Market Barriers

*
However, high cost of therapies entering the market, requirement of adequate reimbursement policies for NSCLC drugs and other factors are creating obstacles in the EGFR Non Small Cell Lung Cancer Market growth.

Scope of EGFR Non Small Cell Lung Cancer Pipeline Drug Insight

*
Coverage: Global

*
Key EGFR Non Small Cell Lung Cancer Companies: Avistone Pharmaceuticals, Black Diamond Therapeutics, Bayer, Bridge Therapeutics, RedCloud Bio, J Ints Bio, Cullinan Oncology, TYK Medicine, and others

*
Key EGFR Non Small Cell Lung Cancer Therapies: PLB1004, BDTX-1535, BAY2927088, BBT-176, H002, JIN-A02, CLN-081, TY-9591, and others

*
EGFR Non Small Cell Lung Cancer Therapeutic Assessment: EGFR Non Small Cell Lung Cancer current marketed and EGFR Non Small Cell Lung Cancer emerging therapies

*
EGFR Non Small Cell Lung Cancer Market Dynamics: EGFR Non Small Cell Lung Cancer market drivers and EGFR Non Small Cell Lung Cancer market barriers

Request for Sample PDF Report for EGFR Non Small Cell Lung Cancer Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/egfr-non-small-cell-lung-cancer-egfr-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. EGFR Non Small Cell Lung Cancer Report Introduction

2. EGFR Non Small Cell Lung Cancer Executive Summary

3. EGFR Non Small Cell Lung Cancer Overview

4. EGFR Non Small Cell Lung Cancer- Analytical Perspective In-depth Commercial Assessment

5. EGFR Non Small Cell Lung Cancer Pipeline Therapeutics

6. EGFR Non Small Cell Lung Cancer Late Stage Products (Phase II/III)

7. EGFR Non Small Cell Lung Cancer Mid Stage Products (Phase II)

8. EGFR Non Small Cell Lung Cancer Early Stage Products (Phase I)

9. EGFR Non Small Cell Lung Cancer Preclinical Stage Products

10. EGFR Non Small Cell Lung Cancer Therapeutics Assessment

11. EGFR Non Small Cell Lung Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. EGFR Non Small Cell Lung Cancer Key Companies

14. EGFR Non Small Cell Lung Cancer Key Products

15. EGFR Non Small Cell Lung Cancer Unmet Needs

16 . EGFR Non Small Cell Lung Cancer Market Drivers and Barriers

17. EGFR Non Small Cell Lung Cancer Future Perspectives and Conclusion

18. EGFR Non Small Cell Lung Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=egfr-non-small-cell-lung-cancer-pipeline-drugs-analysis-report-2024-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-avistone-pharma-black-diamond-therapeutics-bayer-bridge]
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.